- Home
- CRVS vs NPCT Comparison
CRVS vs NPCT Comparison
Compare CRVS & NPCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- NPCT
- Stock Information
- Founded
- CRVS 2014
- NPCT 2020
- Country
- CRVS United States
- NPCT United States
- Employees
- CRVS N/A
- NPCT N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- NPCT Investment Managers
- Sector
- CRVS Health Care
- NPCT Finance
- Exchange
- CRVS Nasdaq
- NPCT Nasdaq
- Market Cap
- CRVS 257.0M
- NPCT 307.4M
- IPO Year
- CRVS 2016
- NPCT N/A
- Fundamental
- Price
- CRVS $3.21
- NPCT $10.68
- Analyst Decision
- CRVS Strong Buy
- NPCT
- Analyst Count
- CRVS 5
- NPCT 0
- Target Price
- CRVS $12.63
- NPCT N/A
- AVG Volume (30 Days)
- CRVS 704.3K
- NPCT 107.1K
- Earning Date
- CRVS 05-05-2025
- NPCT 01-01-0001
- Dividend Yield
- CRVS N/A
- NPCT 9.82%
- EPS Growth
- CRVS N/A
- NPCT N/A
- EPS
- CRVS N/A
- NPCT N/A
- Revenue
- CRVS N/A
- NPCT N/A
- Revenue This Year
- CRVS N/A
- NPCT N/A
- Revenue Next Year
- CRVS N/A
- NPCT N/A
- P/E Ratio
- CRVS N/A
- NPCT N/A
- Revenue Growth
- CRVS N/A
- NPCT N/A
- 52 Week Low
- CRVS $1.30
- NPCT $8.58
- 52 Week High
- CRVS $10.00
- NPCT $10.63
- Technical
- Relative Strength Index (RSI)
- CRVS 29.29
- NPCT 43.09
- Support Level
- CRVS $3.06
- NPCT $10.56
- Resistance Level
- CRVS $3.45
- NPCT $10.76
- Average True Range (ATR)
- CRVS 0.37
- NPCT 0.09
- MACD
- CRVS -0.10
- NPCT -0.00
- Stochastic Oscillator
- CRVS 8.77
- NPCT 43.80
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.